ATE510841T1 - Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase - Google Patents

Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase

Info

Publication number
ATE510841T1
ATE510841T1 AT08762345T AT08762345T ATE510841T1 AT E510841 T1 ATE510841 T1 AT E510841T1 AT 08762345 T AT08762345 T AT 08762345T AT 08762345 T AT08762345 T AT 08762345T AT E510841 T1 ATE510841 T1 AT E510841T1
Authority
AT
Austria
Prior art keywords
disorders
kinase
thiazoliopyrimidines
phosphatidylinositol
kinase inhibitors
Prior art date
Application number
AT08762345T
Other languages
English (en)
Inventor
Timothy Hancox
Neil Pegg
Mandy Beswick
Toby Blench
Elsa Dechaux
Janusz Kulagowski
Alan Nadin
Stephen Price
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0711344A external-priority patent/GB0711344D0/en
Priority claimed from GB0715677A external-priority patent/GB0715677D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE510841T1 publication Critical patent/ATE510841T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AT08762345T 2007-06-12 2008-06-12 Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase ATE510841T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0711344A GB0711344D0 (en) 2007-06-12 2007-06-12 Pharmaceutical compounds
GB0715677A GB0715677D0 (en) 2007-08-10 2007-08-10 Pharmaceutical compounds
PCT/GB2008/002014 WO2008152390A1 (en) 2007-06-12 2008-06-12 Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase

Publications (1)

Publication Number Publication Date
ATE510841T1 true ATE510841T1 (de) 2011-06-15

Family

ID=39731164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08762345T ATE510841T1 (de) 2007-06-12 2008-06-12 Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase

Country Status (7)

Country Link
US (2) US7893060B2 (de)
EP (1) EP2158207B1 (de)
JP (1) JP5539190B2 (de)
CN (1) CN101679456B (de)
AT (1) ATE510841T1 (de)
CA (1) CA2692050A1 (de)
WO (1) WO2008152390A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
JP5539190B2 (ja) * 2007-06-12 2014-07-02 エフ．ホフマン−ラ ロシュ アーゲー チアゾロピリミジン類及びホスファチジルイノシトール−３キナーゼのインヒビターとしてのそれらの使用
KR101584823B1 (ko) 2007-09-12 2016-01-22 제넨테크, 인크. 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
ES2537624T3 (es) * 2007-10-26 2015-06-10 F. Hoffmann-La Roche Ag Derivados purina útiles como inhibidores de la quinasa PI3
JP5520831B2 (ja) 2007-12-19 2014-06-11 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201018681A (en) 2008-07-31 2010-05-16 Genentech Inc Pyrimidine compounds, compositions and methods of use
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CA2987743A1 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Purine derivatives and their use as immunosuppressive agents
JPWO2010125799A1 (ja) 2009-04-27 2012-10-25 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有するウレア誘導体
KR20130026364A (ko) 2009-05-27 2013-03-13 제넨테크, 인크. Ｐ110 델타에 대해 선택적인 비시클릭 피리미딘 ｐｉ3ｋ 억제제 화합물 및 사용 방법
SG182247A1 (en) 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US8288381B2 (en) 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
US8828990B2 (en) 2009-11-12 2014-09-09 Genentech, Inc. N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
KR101467858B1 (ko) * 2009-12-28 2014-12-02 재단법인 생물기술개발중심 ｍＴＯＲ 및 ＰＩ３Ｋ 억제제로서의 신규 피리미딘 화합물
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
EP3399026A1 (de) 2010-06-14 2018-11-07 The Scripps Research Institute Neuprogrammierung von zellen für ein neues zellschicksal
ES2536780T3 (es) * 2010-07-14 2015-05-28 F. Hoffmann-La Roche Ag Compuestos de purina selectivos para I3 p110 delta, y métodos de uso
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
ES2530545T3 (es) 2010-12-16 2015-03-03 Hoffmann La Roche Compuestos tricíclicos inhibidores de la PI3K y métodos de uso
GB201119401D0 (en) * 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
HUE036052T2 (hu) 2011-12-15 2018-06-28 Novartis Ag PI3K aktivitással vagy funkcióval rendelkezõ inhibitorok alkalmazása
BR112014028881A2 (pt) 2012-05-23 2017-06-27 Hoffmann La Roche populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
CN107459508A (zh) 2012-07-20 2017-12-12 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
MX2016003843A (es) 2013-09-27 2017-02-15 Nimbus Iris Inc Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
CN106715424B (zh) 2014-06-05 2020-07-14 拜耳作物科学股份公司 作为农药的双环化合物
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
KR101919189B1 (ko) 2016-02-18 2018-11-15 경북대학교 산학협력단 다중치환 4H-티아졸로[4,5-e][1,4]다이아제핀-5,8-다이온 유도체 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
AT321295B (de) 1971-11-11 1975-03-25 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Thiazolo[5,4-d]-pyrimidin-Derivaten und ihren Salzen
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
KR20010108394A (ko) * 1999-03-26 2001-12-07 다비드 에 질레스 신규 화합물
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2005097746A2 (en) * 2004-04-12 2005-10-20 Torrent Pharmaceuticals Ltd 2-propene-1-ones as hsp 70 inducers
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0508471D0 (en) 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
AU2007243457B2 (en) 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
MX2008013583A (es) 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
KR20090021155A (ko) * 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
CL2007003520A1 (es) 2006-12-07 2008-08-22 Piramed Ltd Genentech Inc Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
JP5500990B2 (ja) 2006-12-07 2014-05-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
JP5539190B2 (ja) * 2007-06-12 2014-07-02 エフ．ホフマン−ラ ロシュ アーゲー チアゾロピリミジン類及びホスファチジルイノシトール−３キナーゼのインヒビターとしてのそれらの使用
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法

Also Published As

Publication number Publication date
CN101679456B (zh) 2012-09-05
JP5539190B2 (ja) 2014-07-02
CA2692050A1 (en) 2008-12-18
US7893060B2 (en) 2011-02-22
EP2158207B1 (de) 2011-05-25
WO2008152390A1 (en) 2008-12-18
EP2158207A1 (de) 2010-03-03
US20110098270A1 (en) 2011-04-28
US8168633B2 (en) 2012-05-01
US20100190769A1 (en) 2010-07-29
CN101679456A (zh) 2010-03-24
JP2010529182A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
ATE510841T1 (de) Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
DE602008004650D1 (de) Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase
MX2009010881A (es) Compuestos farmaceuticos.
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
GB0423653D0 (en) Pharmaceutical compounds
ATE549336T1 (de) Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
MX2008013578A (es) Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
ATE543819T1 (de) Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
WO2008036308A3 (en) Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
UY30323A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
WO2009011850A3 (en) Novel therapeutic compounds
EA201000098A1 (ru) Производные хиназолинамида
EA200802329A1 (ru) Производные триазола ii
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
MA32811B1 (fr) Nouveaux composés
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
MX2008014500A (es) 2,4-diaminopirimidinas como inhibidores de quinasas de ciclo de celulas.
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
SE0301232D0 (sv) Novel use
TW200801018A (en) 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
ECSP099046A (es) Derivados ciclopropil amina
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties